But Gary claims he has tried and failed to get the drug free alternative on the NHS despite it being available for prescription since April 2018. Image showing ActiPatch ® (BioElectronics Corporation, MD, USA) which is a commercially available, over-the-counter medical device used for treating chronic pain (reprinted with permission from BioElectronics Corporation) ( https://www.actipatch.com/) If you’re new to Actipatch and aren’t sure which version of this product is the best for you, there are 4 options you can choose from. Each one works in the same way, but maybe easier to use on different areas of the body: Last month, the Royal College of General Practitioners announced that GPs did not want to prescribe them for long-term use.

As a retired person, I can’t afford to keep shelling out this kind of money. We shouldn’t have to pay when it is available to be prescribed.Prescribing policies on products for which there is no national direction are decided at local level, based on available clinical evidence and cost-effectiveness relative to other products. Full prior agreement about patient’s on-going care must be reached under the shared care agreement.

Primary care prescribers are advised not to take on prescribing of these medicines unless they have been adequately informed by letter of their responsibilities with regards monitoring, side effects and interactions and are happy to take on the prescribing responsibility. A copy of locally approved shared care guidelines should accompany this letter which outlines these responsibilities. Primary care prescribers should then tell secondary care of their intentions as soon as possible by letter so that arrangements can be made for the transfer of care. Primary care prescribers must be familiar with the drug to take on prescribing responsibility or must get the required information. ActiPatch Therapy is medical device that has been developed to treat pain and soft tissue injury. It is CE marked as a class II device, meaning that it has been cleared for sale in the European Union off the shelf, and it is commercially available in the UK. ActiPatch Therapy is simple to use and has no known side effects. The device consists of a control module and a loop antenna and is powered by a battery.

Indication

The OTC Bulletin, the leading global trade publication for over-the-counter healthcare products has chosen its ActiPatch® Musculoskeletal Pain Relief Therapy as the first runner-up for the “ Most Innovative New OTC Product.” Primary care initiation or continuation of treatment is not recommended unless exceptional circumstances such as specialist GP. ActiPatch works by sending out electromagnetic signal pulses into the area where you experience pain. It sends out 1,000 pulses every second, stimulating the neuromodulation of your nerves dampening the feeling of pain with every pulse. It does all this without creating any feeling of vibration, heat, or any other uncomfortable sensation which you may experience with other drug-free pain relief.

BioElectronics’ Smart Insole rides the wave of wearable tech’ that looks likely to crash into the consumer healthcare market. It offers an innovative way to deal with an unglamorous and difficult-to-treat problem.” ActiPatch is free from medication or hormones, and therefore should be fine to use at the same time as your medication. However, if you’re unsure you should always speak to your doctor or Chemist 4 U pharmacist before using this product, as they will help you to be sure this Below are the segments from the March 26 Clear Channel Business Talk Radio interview with BioElectronics CEO Andrew Whelan: Read more at http://www.bielcorp.com/bioelectronics-wins-high-commendation-most-innovative-otc-product-award-otc-bulletin/ ActiPatch® Pain Relief Therapy Featured on Leading Healthcare Show in Spain

Background

I do not want to return to higher levels of medication. And I’m still trying to wean myself off of the remaining prescribed medications too.”